Core Viewpoint - Zai Lab Limited (荃信生物-B) has announced a licensing agreement with Windward Bio's subsidiary, LE2025 Therapeutics AG, for its self-developed drug QX027N, which is expected to enhance the company's revenue potential significantly [1] Group 1: Licensing Agreement - The agreement grants LE2025 exclusive rights to develop and commercialize QX027N globally, excluding mainland China, Taiwan, Hong Kong, and Macau [1] - Zai Lab is entitled to receive up to $700 million in payments, which includes an upfront payment, equity from Windward Bio, and milestone payments related to development and commercialization [1] - Additionally, the company will receive tiered royalties based on the net sales of QX027N in the licensed regions [1] Group 2: Product Information - QX027N is a long-acting bispecific antibody targeting TSLP and IL-13, developed by Zai Lab [1] - The drug has received implied approval for clinical trials from the National Medical Products Administration (NMPA) in November 2025, with acceptance numbers CXSL2500757 and CXSL2500758 [1] - QX027N is intended for the treatment of asthma and atopic dermatitis, and the company has completed the enrollment of the first subject in the domestic Phase I clinical trial [1]
港股异动 | 荃信生物-B(02509)涨超4% 双抗新药QX027N授权出海 可获最高7亿美元付款